Neoadjuvant nivolumab (N) + ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC) Meeting Abstract
| Authors: | Teo, M. Y.; Guercio, B. J.; Pietzak, E. J.; Ponomarev, M.; Regazzi, A. M.; Quinlan, C.; Aggen, D. H.; Donahue, T. F.; Goh, A. C.; Cha, E. K.; Donat, S. M.; Dalbagni, G.; Bochner, B. H.; Funt, S. A.; Bajorin, D. F.; Iyer, G.; Ostrovnaya, I.; Al-Ahmadie, H. A.; Coleman, J.; Rosenberg, J. E. |
| Abstract Title: | Neoadjuvant nivolumab (N) + ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC) |
| Meeting Title: | 2023 ASCO Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2023 Feb 16-18 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-02-20 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.6_suppl.511 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting abstract: 511 -- Accession Number: 162006759 -- Entry Date: In Process -- Revision Date: 20230223 -- Publication Type: Article -- Supplement Title: 2/21/2023 Supplement -- Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA -- NLM UID: 8309333. -- Source: Cinahl |
Altmetric
Citation Impact
BMJ Impact Analytics
